Bristol-Myers Squibb (Canada)

Recent papers from Bristol-Myers Squibb (Canada)

1. CDAI trajectories in patients with rheumatoid arthritis treated with abatacept in real-worldAdvances in Rheumatology · 2026
2. Effect of mavacamten on left ventricular myocardial volume, strain and tissue characteristics in patients with hypertrophic cardiomyopathyEuropean Heart Journal · 2025
3. Bi-ventricular cardiovascular magnetic resonance strain phenotypes are predictive of cardiovascular outcomes in patients with asymptomatic hypertrophic cardiomyopathyEuropean Heart Journal · 2025
4. Early Insights on Mavacamten Usage in Canada: A Retrospective Cohort Study of the Mavacamten Patient Support ProgramCJC Open · 2026
5. 4D phenomics characterization of left ventricular function in obstructive hypertrophic cardiomyopathy patients on mavacamtenJournal of Cardiovascular Magnetic Resonance · 2026
6. Delineation of Management Zones Based on the Agricultural Potential Concept for Potato Production Using Optical Satellite ImagesRemote Sensing · 2025
7. Giving regenerative agriculture an agronomic perspective: a proposed framework from the food and beverage industryFrontiers in Sustainable Food Systems · 2025
8. Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Treatment Recommendations for the Management of Axial SpondyloarthritisThe Journal of Rheumatology · 2024
9. Ab0630 Impact of Joint Involvement on Changes in Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated With AbataceptAnnals of the Rheumatic Diseases · 2024
10. Ab0634 Predictors of Cdai Trajectories in Rheumatoid Arthritis Patients Treated With Abatacept: A Real-World StudyAnnals of the Rheumatic Diseases · 2024
11. Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy2024
12. Does Disopyramide Still Have a Place in the Management of Obstructive Hypertrophic Cardiomyopathy?CJC Open · 2024
13. Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abataceptArthritis Research & Therapy · 2023
14. The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registryLeukemia & lymphoma/Leukemia and lymphoma · 2023
15. Cost-effectiveness of atrial fibrillation screening in Canadian community practiceHeart Rhythm O2 · 2022
16. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registryLeukemia & lymphoma/Leukemia and lymphoma · 2022
17. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysisBMC Cancer · 2022
18. Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and CanadaLung Cancer · 2021
19. Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year dataJournal of Medical Economics · 2021
20. Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patientsCancer Medicine · 2020